Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Reshma Jagsi, Kent A Griffith, Frank Vicini, Thomas Boike, Jacob Burmeister, Michael M Dominello, Inga Grills, James A Hayman, Jean M Moran, Peter Paximadis, Jeffrey D Radawski, Eleanor M Walker, Lori J Pierce
PURPOSE: Understanding acute toxicities after whole-breast radiotherapy is important to inform patients, guide treatment decisions, and target supportive care. We evaluated patient-reported outcomes prospectively collected from a cohort of patients with breast cancer. METHODS: We describe the maximal toxicity reported by 8,711 patients treated between 2012 and 2019 at 27 practices. Multivariable models identified characteristics associated with (1) breast pain, (2) bother from itching, stinging/burning, swelling, or hurting of the treated breast, and (3) fatigue within 7 days of completing whole-breast radiotherapy...
September 28, 2020: Journal of Clinical Oncology
#2
Gagandeep Brar, Laura C Pinheiro, Michael Shusterman, Brandon Swed, Evgeniya Reshetnyak, Orysya Soroka, Frank Chen, Samuel Yamshon, John Vaughn, Peter Martin, Doru Paul, Manuel Hidalgo, Manish A Shah
PURPOSE: SARS-CoV-2 (COVID-19) is a systemic infection. Patients with cancer are immunocompromised and may be vulnerable to COVID-related morbidity and mortality. The objectives of this study were to determine if patients with cancer have worse outcomes compared with patients without cancer and to identify demographic and clinical predictors of morbidity and mortality among patients with cancer. METHODS: We used data from adult patients who tested positive for COVID-19 and were admitted to two New York-Presbyterian hospitals between March 3 and May 15, 2020...
September 28, 2020: Journal of Clinical Oncology
#3
EDITORIAL
Tanguy Y Seiwert, Ana P Kiess
No abstract text is available yet for this article.
September 28, 2020: Journal of Clinical Oncology
#4
Arnon P Kater, Jenny Qun Wu, Thomas Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Julie Dubois, Eric Eldering, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Su Young Kim, Brenda Chyla, Elizabeth Punnoose, Christopher R Bolen, Zoe June Assaf, Yanwen Jiang, Jue Wang, Marcus Lefebure, Michelle Boyer, Kathryn Humphrey, John F Seymour
PURPOSE: In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At the 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and the predictive value of molecular and genetic characteristics. PATIENTS AND METHODS: Patients with CLL were randomly assigned to 2 years of venetoclax (VenR for the first six cycles) or six cycles of BR...
September 28, 2020: Journal of Clinical Oncology
#5
Marjory Charlot
No abstract text is available yet for this article.
September 21, 2020: Journal of Clinical Oncology
#6
EDITORIAL
Antonio C Wolff
No abstract text is available yet for this article.
September 20, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#7
Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton, Joohyuk Sohn, Valentina Guarneri, Morihito Okada, Frances Boyle, Patrick Neven, Javier Cortés, Jens Huober, Andrew Wardley, Sara M Tolaney, Irfan Cicin, Ian C Smith, Martin Frenzel, Desirée Headley, Ran Wei, Belen San Antonio, Maarten Hulstijn, Joanne Cox, Joyce O'Shaughnessy, Priya Rastogi
PURPOSE: Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the first few years. Superior treatment options are needed to prevent early recurrence and development of metastases for this group of patients. Abemaciclib is an oral, continuously dosed, CDK4/6 inhibitor approved for HR+, HER2- advanced breast cancer (ABC)...
September 20, 2020: Journal of Clinical Oncology
#8
EDITORIAL
Abram Recht
No abstract text is available yet for this article.
September 18, 2020: Journal of Clinical Oncology
#9
LETTER
Bas P L Wijnhoven, Sjoerd M Lagarde
No abstract text is available yet for this article.
September 18, 2020: Journal of Clinical Oncology
#10
LETTER
Frederiek Nuytens, Thibault Voron, Guillaume Piessen
No abstract text is available yet for this article.
September 18, 2020: Journal of Clinical Oncology
#11
Michael O Meyers
No abstract text is available yet for this article.
September 18, 2020: Journal of Clinical Oncology
#12
Eric J Roeland, Charles L Loprinzi
No abstract text is available yet for this article.
September 18, 2020: Journal of Clinical Oncology
#13
Gregory Reaman, Dominik Karres, Franca Ligas, Giovanni Lesa, Denise Casey, Lori Ehrlich, Koen Norga, Richard Pazdur
No abstract text is available yet for this article.
September 18, 2020: Journal of Clinical Oncology
#14
Andrea Gallamini, Andrea Rossi, Caterina Patti, Marco Picardi, Alessandra Romano, Maria Cantonetti, Sara Oppi, Simonetta Viviani, Silvia Bolis, Livio Trentin, Guido Gini, Roberta Battistini, Stephane Chauvie, Roberto Sorasio, Chiara Pavoni, Roberta Zanotti, Michele Cimminiello, Corrado Schiavotto, Piera Viero, Antonino Mulé, Federico Fallanca, Umberto Ficola, Corrado Tarella, Luca Guerra, Alessandro Rambaldi
PURPOSE: To investigate the role of consolidation radiotherapy (cRT) in advanced-stage Hodgkin lymphoma (HL) presenting at baseline with a large nodal mass (LNM) in complete metabolic response after doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy. PATIENTS AND METHODS: Advanced-stage (IIB-IVB) HL patients, enrolled in the HD 0607 trial (Clinicaltrial.gov identifier NCT00795613), with both a negative PET after two (PET-2) and six (PET-6) ABVD cycles, who presented at baseline with an LNM, defined as a nodal mass with the largest diameter ≥ 5 cm, were prospectively randomly assigned to receive cRT over the LNM or no further treatment (NFT)...
September 18, 2020: Journal of Clinical Oncology
#15
LETTER
Olivier Huillard, Romain Seban, Francois Goldwasser
No abstract text is available yet for this article.
September 18, 2020: Journal of Clinical Oncology
#16
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J M van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C Lorigan, Alexander C J van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert
PURPOSE: We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. On the basis of 351 recurrence-free survival (RFS) events at a 1.25-year median follow-up, pembrolizumab prolonged RFS (hazard ratio [HR], 0.57; P < .0001) compared with placebo. This led to the approval of pembrolizumab adjuvant treatment by the European Medicines Agency and US Food and Drug Administration...
September 18, 2020: Journal of Clinical Oncology
#17
Graça M Dores, Rochelle E Curtis, Nicole H Dalal, Martha S Linet, Lindsay M Morton
PURPOSE: Mortality for patients with classical Hodgkin lymphoma (cHL) treated during an era characterized in the United States by widespread use of doxorubicin, bleomycin, vinblastine, and dacarbazine and diminishing use of radiotherapy is not well understood. PATIENTS AND METHODS: We identified 20,007 individuals diagnosed with stage I/II (early) or III/IV (advanced) cHL between age 20 and 74 years treated with initial chemotherapy in US population-based cancer registries during 2000-2015 (follow-up through 2016)...
September 18, 2020: Journal of Clinical Oncology
#18
Paul J Bröckelmann, Sven Borchmann, Peter Borchmann, Andreas Engert
No abstract text is available yet for this article.
September 18, 2020: Journal of Clinical Oncology
#19
Sheraz R Markar, Mark I van Berge Henegouwen
No abstract text is available yet for this article.
September 18, 2020: Journal of Clinical Oncology
#20
EDITORIAL
Evandro de Azambuja, Noam Pondé, Richard D Gelber
No abstract text is available yet for this article.
September 16, 2020: Journal of Clinical Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
